World Health Organization (WHO) vaccine experts have officially recommended a full-scale human trial of the Ervebo vaccine in the Democratic Republic of Congo (DRC). The initiative aims to determine whether the vaccine, which is already approved and proven effective against the common Zaire strain of Ebola, can provide cross-protection against the Bundibugyo strain currently circulating in the region.

While Ervebo is a recognized medical tool in the fight against Ebola, its application against the Bundibugyo strain remains experimental in humans. According to health officials, the decision to move toward human trials is based on promising early data, particularly from animal studies, which suggest the vaccine may offer some level of immunity against this rarer variant.

Dr. Paulin Mutombo Beya, deputy director at the Kinshasa School of Public Health, has been involved in discussions regarding the potential public availability of the vaccine. The transition from animal studies to human trials represents a critical step in public health efforts to contain the outbreak. If successful, the trial could provide a vital new defense mechanism for populations currently at risk from the Bundibugyo strain. The WHO has not yet provided a specific timeline for when these human trials will commence, but the recommendation signals a shift toward proactive intervention in the DRC.